ABSTRACT
Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.
Subject(s)
Neoplasms/complications , Venous Thromboembolism/drug therapy , Venous Thromboembolism/etiology , Anticoagulants/therapeutic use , Humans , Premedication , Risk Assessment , Venous Thromboembolism/prevention & controlABSTRACT
These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Promyelocytic, Acute/drug therapy , HumansABSTRACT
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.
Subject(s)
Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/drug therapy , Anemia/etiology , Antineoplastic Agents/therapeutic use , Hematinics/therapeutic use , Hematopoietic Stem Cell Transplantation , Humans , Immunologic Factors/therapeutic use , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/therapy , Prognosis , Transplantation, HomologousABSTRACT
These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recommendations for additional treatment options in patients with chronic lymphocytic leukemia and guidance surrounding the management of hepatitis virus reactivation/infections in high-risk patients with NHL undergoing antitumor therapy.
Subject(s)
Lymphoma, Non-Hodgkin/therapy , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Hepatitis B/blood , Hepatitis B/chemically induced , Hepatitis B/immunology , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus/drug effects , Hepatitis B virus/immunology , Hepatitis B virus/physiology , Hepatitis C/complications , Hepatitis C/drug therapy , Humans , Lenalidomide , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Leukemia, Lymphocytic, Chronic, B-Cell/virology , Lymphoma, Non-Hodgkin/blood , Lymphoma, Non-Hodgkin/virology , Thalidomide/adverse effects , Thalidomide/analogs & derivatives , Thalidomide/therapeutic use , Virus Activation/drug effectsABSTRACT
These NCCN Guidelines Insights summarize several key updates to the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas (NHL) and describe the clinical evidence supporting the updates. The featured updates include changes to the recommendations for treatment options in patients with chronic lymphocytic leukemia (including in elderly or frail patients and patients with poor-risk cytogenetics), guidance surrounding surveillance imaging for follow-up of patients with NHL, and the addition of first-line consolidation options for patients with mantle cell lymphoma.
Subject(s)
Lymphoma, Non-Hodgkin , Clinical Trials as Topic , Guidelines as Topic , Humans , Lymphoma, Non-Hodgkin/classification , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/epidemiology , Lymphoma, Non-Hodgkin/pathologyABSTRACT
Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections provide an overview of the risk factors for infectious complications, recommendations for infectious risk categorization, and strategies for prevention of infections in high-risk patient populations with cancer. Individualized risk evaluation for infections and incorporation of preventative measures are essential components of the overall spectrum of cancer care, and may contribute to optimizing treatment outcomes for patients.
Subject(s)
Bacterial Infections/prevention & control , Immunocompromised Host , Mycoses/prevention & control , Neoplasms/complications , Virus Diseases/prevention & control , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Antiviral Agents/therapeutic use , Bacterial Infections/etiology , Bacterial Infections/immunology , Bacterial Infections/therapy , Hematopoietic Stem Cell Transplantation , Humans , Mycoses/etiology , Mycoses/immunology , Mycoses/therapy , Neoplasms/drug therapy , Neoplasms/immunology , Neutropenia/chemically induced , Neutropenia/complications , Risk Factors , Virus Diseases/etiology , Virus Diseases/immunology , Virus Diseases/therapyABSTRACT
Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk assessment based on cytogenetic and molecular features, treatment options for induction and consolidation therapies for younger and older (age ≥ 65 years) adult patients, and key supportive care considerations.
Subject(s)
Leukemia, Myeloid, Acute/diagnosis , Leukemia, Myeloid, Acute/therapy , Practice Guidelines as Topic , Adult , HumansABSTRACT
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations. It is recommended that patients be treated at specialized centers with expertise in the management of ALL.